Patents by Inventor Sarah Bettigole
Sarah Bettigole has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11780849Abstract: The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to sulfoximine-based inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.Type: GrantFiled: May 3, 2021Date of Patent: October 10, 2023Assignee: Volastra Therapeutics, Inc.Inventors: Derek A. Cogan, Sarah Bettigole, Leon Van Berkom, Piotr Nieczypor, Michael Su, Rutger Folmer
-
Patent number: 11649224Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.Type: GrantFiled: May 6, 2021Date of Patent: May 16, 2023Assignee: Cornell UniversityInventors: Joseph P. Vacca, Dansu Li, Sarah Bettigole
-
Publication number: 20230036933Abstract: The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to triazolopyrimidine and imidazolopyrimidine inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.Type: ApplicationFiled: June 15, 2021Publication date: February 2, 2023Applicant: Volastra Therapeutics, Inc.Inventors: Sarah BETTIGOLE, Michael SU, Derek A. COGAN, Leon VAN BERKOM, Piotr NIECZYPOR, Gydo VAN DER HEIJDEN, Prashanna VIJAYACHANDRAN
-
Publication number: 20230002406Abstract: The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to sulfoximine-based inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.Type: ApplicationFiled: May 3, 2021Publication date: January 5, 2023Applicant: Volastra Therapeutics, Inc.Inventors: Derek A. COGAN, Sarah BETTIGOLE, Leon VAN BERKOM, Piotr NIECZYPOR, Michael SU, Rutger FOLMER
-
Patent number: 11021466Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.Type: GrantFiled: August 16, 2019Date of Patent: June 1, 2021Assignee: Cornell UniversityInventors: Joseph P. Vacca, Dansu Li, Sarah Bettigole
-
Patent number: 10934275Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.Type: GrantFiled: December 1, 2017Date of Patent: March 2, 2021Assignee: Cornell UniversityInventors: Joseph P. Vacca, Dansu Li, Sarah Bettigole
-
Patent number: 10745379Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.Type: GrantFiled: November 8, 2018Date of Patent: August 18, 2020Assignee: Cornell UniversityInventors: Joseph P. Vacca, Dansu Li, Sarah Bettigole
-
Publication number: 20200157079Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.Type: ApplicationFiled: August 16, 2019Publication date: May 21, 2020Applicant: Quentis Therapeutics, Inc.Inventors: Joseph P. Vacca, Dansu Li, Sarah Bettigole
-
Publication number: 20190276434Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.Type: ApplicationFiled: December 1, 2017Publication date: September 12, 2019Applicant: Quentis Therapeutics, Inc.Inventors: Joseph P. Vacca, Dansu Li, Sarah Bettigole
-
Patent number: 10392367Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.Type: GrantFiled: May 31, 2018Date of Patent: August 27, 2019Assignee: Quentis Therapeutics, Inc.Inventors: Joseph P. Vacca, Dansu Li, Sarah Bettigole
-
Publication number: 20190169160Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.Type: ApplicationFiled: November 8, 2018Publication date: June 6, 2019Inventors: Joseph P. VACCA, Dansu LI, Sarah BETTIGOLE
-
Publication number: 20180346446Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.Type: ApplicationFiled: May 31, 2018Publication date: December 6, 2018Inventors: Joseph P. VACCA, Dansu LI, Sarah BETTIGOLE
-
Publication number: 20180346447Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.Type: ApplicationFiled: May 31, 2018Publication date: December 6, 2018Inventors: Joseph P. Vacca, Dansu Li, Sarah Bettigole
-
Patent number: 9956236Abstract: The invention provides, e.g., compositions and methods for increasing activation of immune cells.Type: GrantFiled: February 7, 2012Date of Patent: May 1, 2018Assignee: Cornell UniversityInventors: Laurie H. Glimcher, Sarah Bettigole, Fabio Martinon
